TrialCancer communications (London, England)2025

An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial.

Jiayu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.